36 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Shafer, Infectious Disease Specialist in Stanford, CA?
Dr. Robert Shafer, MD is an Infectious Disease Specialist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 36 years. Dr. Shafer graduated from New York University School of Medicine. Dr. Shafer is fluent in English, and is currently seeing new patients. Dr. Shafer’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Shafer’s office at (650) 723-4000.
Where did Dr. Shafer go to medical school and complete their residency?
Medical School: New York University School of Medicine
What languages does Dr. Shafer speak?
Dr. Shafer and their clinical team can communicate with patients in the following languages:
English
What conditions does an Infectious Disease Specialist like Dr. Shafer typically treat?
As an Infectious Disease Specialist, Dr. Shafer diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Shafer. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Long COVID
- COVID-19 (Coronavirus Disease 2019)
- Post-COVID Syndrome
- Long-Haul COVID
- Chronic COVID
ICD-10 Codes:
- U099: Post COVID-19 condition, unspecified
What procedures does an Infectious Disease Specialist like Dr. Shafer typically perform?
As an Infectious Disease Specialist, procedures performed by Dr. Robert Shafer may include:
- Epidemiology Consultation
- Epidemiology Follow Up
- HIV / AIDS Consultation
- HIV / AIDS Follow Up
- Human Papillomavirus (HPV) Vaccine
- Infection Follow Up
- Lumbar Puncture
- Pertussis Vaccine
Please contact Dr. Shafer's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Shafer accept my insurance?
Dr. Shafer accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Shafer accept in Stanford, CA?
Dr. Shafer in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Centene Corporation
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
Santa Cruz County
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Shafer's office located?
Recognitions
Publications
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance
, 2014
Prototypical Recombint Multi-Protease
, 2013
Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006
, 2013
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first
, 2013
Collinearity of protease mutations in HIV-1 samples with high
, 2013
Low-Level Persistence of Drug Resistance Mutations in Hepatitis B Virus
, 2013
Panel of Prototypical Recombint Infectious Molecular Clones Resistant to Nevirapine, Efavirenz
, 2012
A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir
, 2012
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
, 2012
The efficacy of an anti-CD4 monoclol antibody for HIV-1 treatment
, 2011
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
, 2011
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C
, 2010
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
, 2010
Minority Variants Associated with Transmitted
, 2009
Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease
, 2009
Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms
, 2009
Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside
, 2009
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
, 2009
Low-Abundance Drug-Resistant HIV-1 Variants
, 2009
A transitiol endogenous lentivirus from the genome of a basal primate
, 2008
Characterization of mutation spectra with ultra-deep pyrosequencing
, 2007
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
, 2007
Genotypic predictors of human immunodeficiency virus type 1 drug resistance
, 2006
Ratiole and uses of a public HIV drug-resistance database
, 2006
Web resources for HIV type 1 genotypic-resistance test interpretation
, 2006
HIV-1 pol mutation frequency by subtype and treatment experience
, 2006
HIV-1 protease and reverse-transcriptase mutations
, 2005
Drug resistance and antiretroviral drug development
, 2005
Panel of prototypical infectious molecular HIV
, 2005
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype
, 2005
Comparison of four-drug regimens
, 2003
Colinearity of reverse transcriptase inhibitor resistance mutations detected by population
, 2003
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person
, 2003
Extended spectrum of HIV
, 2003
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease
, 2003
Human immunodeficiency virus reverse transcriptase and protease sequence database
, 2003
Genotypic testing for human immunodeficiency virus type 1 drug resistance
, 2002
Human immunodeficiency virus type 1 reverse transcriptase
, 2000
HIV-1 genotypic resistance patterns predict response to saquivir
, 1999
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1
, 1999
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV
, 1998
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency
, 1997
Tuberculosis in patients infected with human immunodeficiency virus: Perspective on the past decade
, 1996
Predictors of survival in HIV-infected tuberculosis patients
, 1996
TEMPORAL TRENDS AND TRANSMISSION PATTERNS DURING THE EMERGENCE OF MULTIDRUG
, 1995
COMBITION THERAPY WITH ZIDOVUDINE AND DIDANOSINE SELECTS FOR DRUG-RESISTANT HUMAN
, 1994
EXOGENOUS REINFECTION WITH MULTIDRUG-RESISTANT MYCOBACTERIUM
, 1993
EXTRAPULMORY TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
, 1991
HIV-1 fitness landscape models for indivir treatment pressure using observed evolution in
, 2013
Drug Resistance Mutations in HIV-1.
Cooperative Effects of Drug-Resistance Mutations in the Flap Region of HIV-1 Protease
, 2013
Update of the drug resistance mutations in HIV-1: March 2013.
, 2013
In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico
, 2013
T Cell Activation Markers
, 2012
Development of Elvitegravir Resistance
, 2012
Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Alysis Tool
, 2012
Whole-genome sequencing of the efficient industrial fuel
, 2012
Standardized representation
, 2012
Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase
, 2012
The HIVdb System for HIV-1 Genotypic Resistance Interpretation
, 2012
A multifaceted alysis of HIV-1 protease multidrug resistance phenotypes
, 2011
2011 update of the drug resistance mutations in HIV-1.
, 2011
Loss of Protease Dimerization Inhibition Activity of Daruvir
, 2011
Prediction of response to antiretroviral therapy by human experts
, 2011
Hepatitis B virus reverse transcriptase sequence variant database for sequence alysis
, 2010
A classification model for G-to
, 2010
HIV-1 Integrase Sequence Variability in Antiretroviral ive Patients
, 2010
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfivir fitness l
, 2010
Long-term increase in CD4
, 2010
Constrained patterns of covariation
, 2010
Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation
, 2010
African Mitochondrial D Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy
, 2010
Predicting Tipravir and Daruvir Resistance Using Genotypic, Phenotypic
, 2010
Public database for HIV drug resistance in southern Africa
, 2010
Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in a Novel Integrase
, 2010
The calibrated population resistance tool
, 2009
Human Immunodeficiency Virus Type 1 Isolates with the Reverse Transcriptase
, 2009
Predicting the Response to Combition Antiretroviral Therapy
, 2009
The challenge of antiretroviral drug resistance in HIV-1-infected children
, 2009
Incomplete Reconstitution of T Cell Subsets on Combition Antiretroviral Therapy
, 2009
Biomarker discovery using targeted maximum-likelihood estimation
, 2009
Advantages of predicted phenotypes
, 2009
A highly prevalent and genetically diversified Picorviridae genus in South Asian children
, 2008
Virologic Response to Lopivir-Ritovir
, 2008
Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral
, 2008
Bayesian network alyses of resistance pathways against efavirenz and nevirapine
, 2008
Ratiol use of antiretroviral therapy in low-income and middle-income countries
, 2008
tural variation of HIV-1 group M integrase
, 2008
Viral population estimation using pyrosequencing
, 2008
Viral population estimation using pyrosequencing.
, 2008
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
, 2008
Sequence editing by Apolipoprotein B R-editing catalytic component-B
, 2008
Hemochromatosis gene polymorphisms, mitochondrial haplogroups
, 2008
The mitochondrial pharmacogenomics of haplogroup T
, 2008
Dymics of total, linear nonintegrated, and integrated HIV-1 D in vivo and in vitro
, 2008
Multiple independent origins of a protease inhibitor resistance mutation
, 2008
Consensus drug resistance mutations for epidemiological surveillance
, 2008
A highly divergent picorvirus in a marine mammal
, 2008
Prevalence of daruvir resistance-associated mutations
, 2007
World antimalarial resistance network (WARN) III: Molecular markers for drug resistant malaria
, 2007
Educatiol attainment and response to HAART during initial therapy for HIV-1 infection
, 2007
Virologic efficacy of boosted double versus boosted single protease inhibitor therapy
, 2007
Simple PCR Assays Improve the Sensitivity of HIV-1 Subtype B Drug Resistance Testing
, 2007
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
, 2007
Improved prediction of response to antiretroviral combition therapy using the genetic barrier to
, 2007
Knowledge integration of software for HIV drug resistance research.
, 2007
Case files from Stanford University Medical Center: ten years of HAART
, 2007
N88D facilitates the co
, 2006
Multilocus genetic interactions and response to efavirenz-containing regimens
What is Dr. Shafer's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Shafer's National Provider Identifier (NPI) number is 1659494904.
What common questions do patients ask about Dr. Shafer?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Shafer
What is Dr. Robert Shafer's specialty?
Dr. Shafer is a Infectious Disease Specialist near Stanford, CA.
What does an Infectious Disease Specialist do?
An internist who deals with infectious diseases of all types and in all organ systems. Conditions requiring selective use of antibiotics call for this special skill. This physician often diagnoses and treats AIDS patients and patients with fevers which have not been explained. Infectious disease specialists may also have expertise in preventive medicine and travel medicine.
Is this Dr. Robert Shafer affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Shafer is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Infectious Disease Specialist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Infectious Disease Specialist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Robert Shafer accepting new patients in Stanford, CA?
Yes, Dr. Robert Shafer is accepting new patients at this time.
Does Dr. Robert Shafer offer online booking?
Please contact Dr. Shafer's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Robert Shafer?
Please contact Dr. Shafer's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Other Infectious Disease Specialist Near Stanford, CA
Infectious Disease Specialist
Accepting patientsInfectious Disease Specialist
Accepting patients
Infectious Disease Specialist
Accepting patients